Spinal cord stimulation in the treatment of chronic pain syndromes

2016 ◽  
Vol 80 (2) ◽  
pp. 47 ◽  
Author(s):  
N. P. Denisova ◽  
D. Yu. Rogov ◽  
D. A. Rzaev ◽  
E. A. Khabarova ◽  
A. B. Dmitriev
1986 ◽  
Vol 233 (1) ◽  
pp. 16-18 ◽  
Author(s):  
H. P. Vogel ◽  
B. Heppner ◽  
N. H�mbs ◽  
J. Schramm ◽  
C. Wagner

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Anshit Goyal ◽  
Archis Bhandarkar ◽  
Mohammed A Alvi ◽  
Yagiz U Yolcu ◽  
Mohamad Bydon

Abstract INTRODUCTION In this study, we sought to determine the trends in cost and utilization of spinal cord stimulation (SCS) as well as better understand the drivers of cost associated with this procedure. METHODS The National Inpatient Sample (NIS) was queried for inpatient admissions between 2008 and 2014 where SCS was performed. We then determined the rates and costs of SCS performed in this time frame to treat diagnoses that we classified as cervical-level pathologies, thoracic-level pathologies, lumbosacral-level pathologies, chronic pain syndromes, or device-related complications. Multivariable linear regression was then performed to establish the particular patient, hospital, and clinical factors driving costs of SCS admissions. RESULTS A total of 6209 admissions were included in this analysis. The overall rate of SCS procedures performed has decreased by 44% from 2008 to 2014 (139 to 77 procedures per million inpatient admissions). The estimated national economic burden of SCS has also decreased by 28% in this time span ($115 million-$83 million). Lumbosacral-level pathologies, such as postlaminectomy syndrome of the lumbar spine, accounted for the greatest share of inpatient admissions (36% in 2014) and the greatest share of the cost associated with SCS (37% in 2014). Chronic pain syndromes accounted for the second largest share of inpatient admissions (24% in 2014) and costs (23% in 2014). Length of stay, a primary diagnosis of device-related complications, and the comorbidities of obesity and depression emerged as top predictors of admission cost (P < .001). CONCLUSION In this analysis from a national database, we determined that the rate and costs associated with inpatient SCS have been decreasing and also found several patient, hospital, and clinical factors to target for further cost-reduction efforts.


2010 ◽  
Vol 16 (2) ◽  
pp. 68-71
Author(s):  
D. A. Rzaev ◽  
V. V. Rudenko ◽  
I. L. Pudovkin ◽  
A. P. Tatarintsev ◽  
D. S. Godanyuk

In the article initial experience of spinal cord stimulation for chronic pain syndromes is described. The trial was done for 62 patients, in 52 cases trial was successful and subcutaneous pulse generator were implanated. Maximal follow-up is 26 months. The level of pain evaluates at VAS. Permanent pain-relieve results were achieved in 46 patients (74,2%). These results correspond to literature data.


Spinal Cord ◽  
1998 ◽  
Vol 36 (10) ◽  
pp. 671-682 ◽  
Author(s):  
Inge AM ten Vaarwerk ◽  
Michiel J Staal

2020 ◽  
pp. 1-12
Author(s):  
Irene E. Harmsen ◽  
Dilafruz Hasanova ◽  
Gavin J.B. Elias ◽  
Alexandre Boutet ◽  
Clemens Neudorfer ◽  
...  

<b><i>Background:</i></b> Spinal cord stimulation (SCS) is a neuromodulation technology widely used in the treatment of intractable chronic pain syndromes. SCS is now being applied more broadly as a possible therapy for a range of indications, including neurological, cardiac, and gastrointestinal disorders. Ongoing research in this field is critical in order to gain further insights into the mechanisms of SCS, determine its role in new indications, and refine programming techniques for the optimization of therapeutic outcomes. <b><i>Objective:</i></b> To assess the state of SCS-related human research by cataloging and summarizing clinical trials that have been recently completed or are currently underway in this field. <b><i>Methods:</i></b> A search was conducted for clinical trials pertaining to SCS using the ClinicalTrials.gov database. Trials were analyzed to generate a detailed overview of ongoing SCS-related research. Specifically, trials were categorized by intervention, trial start date, study completion status, clinical phase, projected subject enrollment, condition, country of origin, device manufacturer, funding source, and study topic. <b><i>Results:</i></b> In total, 212 relevant clinical trials were identified. 175 trials (82.5%) involved invasive SCS, while the remaining 37 trials (17.5%) used noninvasive forms of spinal stimulation. Most trials examined the efficacy of SCS for chronic pain syndromes or new indications, while others assessed different stimulation parameters. The studies spanned &#x3e;27 different disorders, with almost 20% of trials pertaining to conditions other than chronic pain syndromes. The majority of SCS trials were US-based (55.7% of studies), but many countries (e.g., Belgium and UK) are becoming increasingly active. The ratio of investigator-sponsored to industry-sponsored trials was 2:1. Emphasizing the need to optimize therapeutic outcomes of SCS, one-quarter of trials predominantly focused on the assessment of alternative stimulation parameters such as burst or high-frequency stimulation. <b><i>Conclusions:</i></b> A large number of clinical trials of SCS are underway. Improvements in the treatment of pain and novel indications for SCS constitute the majority of studies. This overview of SCS-related clinical trials provides a window into future new indications, novel stimulation techniques, and a heightened understanding of the mechanisms of action.


Sign in / Sign up

Export Citation Format

Share Document